SAN DIEGO, CA--(Marketwired - Mar 12, 2014) - Aegis Therapeutics LLC's Intravail® technology has been successfully formulated with phenylephrine in compressed tablets, dramatically improving oral ...
SAN DIEGO, Feb. 20, 2019 /PRNewswire/ -- Neurelis, Inc. announced today that its Intravail® licensing partner, ARS Pharmaceuticals, Inc., received Fast Track designation from the FDA for ARS-1, its ...
SAN DIEGO, CA--(Sep 24, 2012) - Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,268,791 providing fast acting formulations for triptans, a class of drugs that are ...
DANBURY, Conn., June 8, 2012-- Biodel Inc. and Aegis Therapeutics, LLC (Aegis) today announced a partnership providing Biodel an exclusive worldwide license to Aegis' proprietary ProTek® and ...
SAN DIEGO, Calif.--(BUSINESS WIRE)--ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic ...
On July 19, 2017, Opiant Pharmaceuticals Inc. (OPNT) announced results from a Phase 1 study of OPNT002, an intranasally (IN) administered formulation of the opioid antagonist naltrexone hydrochloride.
SAN DIEGO, May 4, 2020 /PRNewswire/ -- Neurelis, Inc., announced today that the American Academy of Allergy, Asthma & Immunology (AAAAI) presented promising results for ARS Pharmaceuticals' lead asset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results